Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Michael Patrick Achiam

Status

Completed

Conditions

Esophagus Cancer, Adenocarcinoma

Treatments

Other: uPAR immunohistochemistry

Study type

Interventional

Funder types

Other

Identifiers

NCT04669951

uPAR ECV

Details and patient eligibility

About

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Full description

Sections of the tumor tissue will be HE stained.
Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry.
Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern.
A semiqualitative scale corresponding to the level of uPAR expression will be made.
Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern.
An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years old.
Patients who underwent curatively intended surgery for gastroesophageal cancer
Patients who underwent surgery after 01-01-2016.

Exclusion criteria

Patients who applied for an exception from medical research at the "National Registry of Tissue Use."
Patients with other histological subtypes than adenocarcinoma.